HOMOLOGOUS RECOMBINATION DEFICIENCY
Clinical trials for HOMOLOGOUS RECOMBINATION DEFICIENCY explained in plain language.
Never miss a new study
Get alerted when new HOMOLOGOUS RECOMBINATION DEFICIENCY trials appear
Sign up with your email to follow new studies for HOMOLOGOUS RECOMBINATION DEFICIENCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Prostate cancer study on race and drug response pulled before starting
Disease control TerminatedThis study aimed to see if a person's race changes how well a combination of two drugs (niraparib and abiraterone acetate plus prednisone) works for a certain type of advanced prostate cancer. It planned to enroll Black, Hispanic, White, and Native American men whose cancer had s…
Matched conditions: HOMOLOGOUS RECOMBINATION DEFICIENCY
Phase: PHASE2 • Sponsor: Latin American Cooperative Oncology Group • Aim: Disease control
Last updated May 17, 2026 04:35 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new oral drug, MOMA-313, alone or with another drug (olaparib) in people with advanced solid tumors that have a specific DNA repair problem (HR deficiency). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. …
Matched conditions: HOMOLOGOUS RECOMBINATION DEFICIENCY
Phase: PHASE1 • Sponsor: MOMA Therapeutics • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Lung cancer clue: DNA repair flaw may guide future treatments
Knowledge-focused OngoingThis study examines 100 people with a certain type of advanced lung cancer (EGFR-mutated NSCLC) to see how often they have a DNA repair problem called HRD. Researchers will look at tumor samples and medical records to find links between HRD and how the cancer behaves. The goal is…
Matched conditions: HOMOLOGOUS RECOMBINATION DEFICIENCY
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated May 17, 2026 04:34 UTC